Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients
Status:
Not yet recruiting
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The aim is to demonstrate a decrease in complications among ambulatory patients who are
diagnosed with mild COVID-19 by treating them with nitazoxanide for 7 to 14 days on top of
standard care compared to patients who receive standard care and placebo only.